The DZIF has initiated an online consultation service for treating cases of multidrug-resistant tuberculosis. Here, doctors can submit their cases and get advice for further treatment from experts at
30 years after HIV was discovered to be the cause of the acquired immune deficiency syndrome AIDS, and despite intensive research, no vaccine or cure has yet been found. An international team of
The initial results of a clinical Phase I trial of a potential vaccine against the dreaded Ebola virus are now available. At the Hamburg-Eppendorf University Medical Center (UKE), in Geneva
PanACEA, the Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics, presented the results of its most recent phase IIb study. The most exciting finding from the study is that high
An international group of scientists unraveled for the first time the global spread of multidrug resistant (MDR) Mycobacterium tuberculosis (MTB) strains. The study shows that efficient tuberculosis
An international team of researchers has discovered an antibiotic compound which is effective against a broad spectrum of pathogens. First tests have shown that it does not generate resistance. A
The DZIF Transplant Cohort, which was officially founded as an association in February 2014, has completed its preparations. The association can now begin with recruiting first patients and collecting
Researchers from the German Center for Infection Research (DZIF) have confirmed the spread of a “multidrug-resistant plasmid” in a hospital. This plasmid is a mobile genetic element which can transfer
(26/11/2014) Virologist Stephan Urban from the University of Heidelberg will receive the DZIF Prize for Translational Infection Research, worth 5000 Euros. It will be awarded for the first time at the
Researchers at the University of Tübingen are testing an Ebolavaccine in healthy adults in Gabon. The first voluntary trial participants are being vaccinated today.
